DrugPatentWatch Database Preview
Tafamidis - Generic Drug Details
Try a free trial
See Plans and Pricing
What are the generic drug sources for tafamidis and what is the scope of tafamidis freedom to operate?
Tafamidis
is the generic ingredient in two branded drugs marketed by Foldrx Pharms and is included in two NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.Tafamidis has fifty patent family members in twenty-three countries.
One supplier is listed for this compound.
Summary for tafamidis
| International Patents: | 50 |
| US Patents: | 5 |
| Tradenames: | 2 |
| Applicants: | 1 |
| NDAs: | 2 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 42 |
| Clinical Trials: | 18 |
| Patent Applications: | 31 |
| DailyMed Link: | tafamidis at DailyMed |
Synonyms for tafamidis
| 2-(3,5-Dichloro-phenyl)-benzooxazole-6-carboxylic acid |
| 2-(3,5-Dichlorophenyl)-1,3-Benzoxazole-6-Carboxylic Acid |
| 2-(3,5-Dichlorophenyl)-6-benzoxazole carboxylic acid |
| 2-(3,5-Dichlorophenyl)-6-benzoxazolecarboxylic Acid |
| 2-(3,5-dichlorophenyl)benzoxazole-6-carboxylic acid |
| 3096AH |
| 3MI |
| 4his |
| 594839-88-0 |
| 6-Benzoxazolecarboxylic acid, 2-(3,5-dichlorophenyl)- |
| 839D880 |
| 8FG9H9D31J |
| A14111 |
| AK222900 |
| AKOS017550076 |
| AN-27718 |
| BCP29089 |
| BDBM50197883 |
| C14H7Cl2NO3 |
| CHEBI:78538 |
| CHEMBL2103837 |
| CS-2821 |
| D09673 |
| DB-072645 |
| DB11644 |
| Discontinued until Pfizer approves it for our agreement"" |
| DTXSID00208185 |
| FT-0674793 |
| Fx 1006 |
| FX-1006 |
| FX-1006A|||2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid |
| GTPL8378 |
| HY-14852 |
| KS-00000TIG |
| MFCD16621109 |
| SCHEMBL442508 |
| Tafamidis (USAN/INN) |
| Tafamidis [USAN:INN] |
| tafamidisum |
| UNII-8FG9H9D31J |
| VS-0125 |
| Z2588039578 |
| ZINC43206271 |
US Patents and Regulatory Information for tafamidis
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Foldrx Pharms | VYNDAMAX | tafamidis | CAPSULE;ORAL | 212161-001 | May 3, 2019 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for tafamidis
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2010201263 | ➤ Sign Up |
| China | 1747965 | ➤ Sign Up |
| Japan | 4665076 | ➤ Sign Up |
| European Patent Office | 1988397 | ➤ Sign Up |
| Mexico | 2017002954 | ➤ Sign Up |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for tafamidis
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1587821 | 1290005-6 | Sweden | ➤ Sign Up | PRODUCT NAME: TAFAMIDIS; REG. NO/DATE: EU/1/11/717/001 20111116 |
| 1587821 | 126 5003-2012 | Slovakia | ➤ Sign Up | PRODUCT NAME: TAFAMIDIS MEGLUMIN; REGISTRATION NO/DATE: EU/1/11/717/001 20111116 |
| 1587821 | CR 2012 00006 | Denmark | ➤ Sign Up | PRODUCT NAME: TAFAMIDIS (SOM MEGLUMIN); REG. NO/DATE: EU/1/11/717/001 20111116 |
| 1587821 | 2012/007 | Ireland | ➤ Sign Up | PRODUCT NAME: VYNDAQEL- TAFAMIDIS MEGLUMINE; REGISTRATION NO/DATE: EU/1/11/717/001 20111116 |
| 1587821 | 382 | Finland | ➤ Sign Up | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
